Abstract 156P
Background
Abnormal collagen fiber architectures in tumor fibrosis affect prognosis and treatment response in pancreatic cancer (PC) patients. Increased fibrotic activity releases collagen metabolites into the bloodstream. The aim was to explore these metabolites to cluster PC patients into tumor fibrosis endotypes and evaluate overall survival (OS).
Methods
Serum was collected from patients with PC prior to chemotherapy or resection and included in the BIOPAC Study (ID: NCT03311776) (stage I (n=15), Stage II (n=201), stage III (n=164) and stage 4 (n=434)). Principal component analysis was performed on the levels of five collagen metabolites (Table) measured by ELISAs. K-means clustering was used to discover clusters and Kaplan-Meier curves and the cox proportional hazards model used to dicover associations with OS. Table: 156P
Biomarker name | collagen metabolite |
C3M | Neo-epitope of MMP-9 mediated degradation of type III collagen |
PRO-C3 | Released N-terminal pro-peptide of type III collagen |
PRO-C5 | Released C-terminal pro-peptide of type V collagen |
PRO-C6 | C-terminal of released C5 domain of type VI collagen α3 chain (endotrophin) |
PRO-C11 | Released N-terminal pro-peptide of type XI collagen |
Results
Three putative endotypes (cluster A, B, C) were identified. Patients in cluster B had higher C3M, PRO-C5 and PRO-C11 levels compared to cluster A, whereas patients in cluster C had higher PRO-C3 and PRO-C6 levels compared to cluster A. Patients with endotype A had a median OS of 332 days vs. 185 and 144 days for endotype B and C (p<0.001). Compared to endotype A, both endotype B (HR=1.56, 95% CI 1.28–1.91, p<0.001) and endotype C (HR=1.69, 95% CI 1.26–2.26, p<0.001) were predictors of poor OS when corrected for age, sex, performance status, body mass index, diabetes, cachexia, stage, number of metastatic sites, and CA19-9.
Conclusions
Clustering of patients with PC based on five collagen-derived metabolites measured in serum identifies 3 distinct endotypes that were associated with poor OS independent of other common risk factors. These findings indicate that non-invasive collagen biomarkers can be used to identify fibrotic endotypes in patients with PC and that such endotypes may inform on patient prognostication.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Danish Research Foundation.
Disclosure
J. Thorlacius-Ussing, N.I. Nissen, C. Jensen, M. Karsdal, N. Willumsen: Financial Interests, Institutional, Full or part-time Employment: Nordic bioscience A/S. All other authors have declared no conflicts of interest.
Resources from the same session
155P - Exploring the utility of serum anti-tNASP antibodies as a screening biomarker in prostate, pancreatic, and ovarian cancer
Presenter: Oleg Alekseev
Session: Poster session 01
157P - CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Presenter: Pengfei Yu
Session: Poster session 01
158P - In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas
Presenter: Arturo Gonzalez-Vilanova
Session: Poster session 01
159P - Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
Presenter: Shujuan NI
Session: Poster session 01
161P - Biomarkers of neoadjuvant combinational therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
Presenter: Yue Wang
Session: Poster session 01
162P - MR imaging biomarkers profiles in patients with prostate cancer treated with androgen deprivation therapy
Presenter: Angel Luis Sanchez Iglesias
Session: Poster session 01
163P - Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Presenter: Jair Bar
Session: Poster session 01
164P - Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
Presenter: Astrid Kramer
Session: Poster session 01
165P - Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): A sub analysis of PHERGain trial
Presenter: Maria Gion Cortes
Session: Poster session 01